Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.69 USD
Change Today -0.185 / -3.79%
Volume 2.0M
RIGL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Open
$4.92
Previous Close
$4.88
Day High
$5.20
Day Low
$4.47
52 Week High
04/27/15 - $5.20
52 Week Low
10/22/14 - $1.56
Market Cap
412.9M
Average Volume 10 Days
1.0M
EPS TTM
$-1.03
Shares Outstanding
88.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RIGEL PHARMACEUTICALS INC (RIGL)

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. It is developing fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and Phase II clinical trials for IgA nephropathy; R348, a topical JAK/SYK inhibitor that is in Phase II clinical trials for the treatment of dry eye in ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has a license agreement with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a license agreement with BerGenBio AS for the development and commercialization of an oncology program; a collaboration agreement with Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.

127 Employees
Last Reported Date: 03/3/15
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $551.7K
Co-Founder, President of Discovery & Research...
Total Annual Compensation: $559.6K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Executive Vice President of Corporate Affairs...
Total Annual Compensation: $475.5K
Compensation as of Fiscal Year 2014.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported a net loss of $22.3 million, or $0.25 per basic and diluted share, compared to a net loss of $16.9 million, or $0.19 per basic and diluted share, in the fourth quarter of 2013. Contract revenues from collaborations of $8.3 million against $5.75 million in 2013, were comprised of non-refundable payments earned from AstraZeneca AB (AZ) as a result of its continued development of R256 in asthma. Loss from operations was $22.368 million against $16.944 million a year ago. For the year, the company reported contract revenues from collaborations of $8.3 million and a net loss of $90.9 million, or $1.04 per basic and diluted share, compared to contract revenues from collaborations of $7.2 million and a net loss of $89.0 million, or $1.02 per basic and diluted share, in 2013. Contract revenues from collaborations in 2014 and 2013 included $8.3 million and $5.8 million, respectively, of non-refundable payments earned from AZ, and a non-refundable payment of $1.4 million in 2013 from Daiichi Sankyo related to their investigational new drug application filing for an oncology compound. Loss from operations was $91.249 million against $89.469 million a year ago.

Rigel Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 03, 2015

Rigel Pharmaceuticals, Inc. announced that they will report Q4, 2014 results on Mar 03, 2015

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab). Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30 million upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309 million for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration. Within the immune system, TGF beta often plays an immunosuppressive role by potently suppressing effector cell proliferation and function while simultaneously promoting differentiation of certain suppressive T-cells. This master regulator is often present within tumor microenvironments and can significantly dampen anti-tumor host immune responses. Current evidence suggests that TGF beta can arise from many sources, including the cancer itself, surrounding cells and infiltrating macrophages. Developing a drug that inhibits TGF beta signaling in cancer patients has the potential to counteract an important mechanism used by cancers to escape immuno-surveillance, thereby making this signaling pathway an appealing therapeutic target for immuno-oncology related applications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $4.69 USD -0.185

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.02 USD -0.10
CrystalGenomics Inc 12,700 KRW +150.00
CTI BioPharma Corp $1.87 USD -0.09
Exelixis Inc $2.83 USD -0.25
Progenics Pharmaceuticals Inc $5.71 USD -0.32
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.9x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.